Company / Net Income
Akebia Therapeutics, Inc. Net Income History
FY2014-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$5.3M
FY2025
5-year range
-$279.7M / -$5.3M
FY2021-FY2025
Trend
+92.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Net Income has fluctuated over the past 10 years, ranging from -$280M in FY2021 to -$5M in FY2025.
Based on SEC 10-K filings.
-$5M in FY2025.
Improved from -$52M to -$5M over the past 2 years.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, net income increased 92.3% year-over-year.
- Lowest net income in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score -2.76 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$5.3M | +92.3% |
| FY2024 | -$69.4M | -33.7% |
| FY2023 | -$51.9M | +44.9% |
| FY2022 | -$94.2M | +66.3% |
| FY2021 | -$279.7M | -94.8% |
| FY2020 | -$143.6M | -94.9% |
| FY2019 | -$73.7M | +45.7% |
| FY2018 | -$135.7M | -931.0% |
| FY2015 | -$13.2M | -60.7% |
| FY2014 | -$8.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026